natgillin/translations-raw huggingface dataset:
The compound for use of any one of claims 1-3, wherein the peptide is linked at its N-terminus to the conjugating group by a disulfide bond. 
gdje su barem dva od X2, X3 i X4 nezavisno kationska podjedinica; i gdje je peptid vezan na svom N-kraju disulfidnom vezom za konjugirajuću skupinu.
The dsRNA duplex of the protein-binding segment can have a length from about 6 base pairs (bp) to about 50bp. 
(i) navedeni dsRNA dupleks ima duljinu od 8 parova baza (bp) do 15 bp;
The pharmaceutical composition for use in a method of treating depression according to claim 2 or claim 3, wherein administering L-4-chlorokynurenine produces a blood plasma level of 7-chlorokynurenic acid from about 15 ng/mL to about 550 ng/mL. 
Farmaceutski pripravak za upotrebu u postupku liječenja depresije prema patentnom zahtjevu 2 ili 3, naznačen time da primjena L-4-klorokinurenina stvara u krvnoj plazmi koncentraciju 7-klorokinurenske kiseline od oko 15 ng/mL do oko 550 ng/mL.
As is the case with the above embodiments as described with figs. 2-5b flange 45 extending downward from the collar 23 and protecting the cup-shaped part 40 can be provided with one or more ports through which a dispensing tube (not shown) can be extended. 
Kao u slučaju gore opisanih izvedbi na slikama 2-5b, prirubnica 45, koja se proteže prema dolje iz prstena 23, i zaštitni dio 40 oblika čašice mogu se predvidjeti s jednim ili više ulaza, kroz koje se može provući cijev za točenje (koja nije prikazana) .
The aqueous solution may be applied to the produce in any suitable or customary manner, e.g., by dipping the produce in the tank or vat of the solution, by spraying the solution onto the produce, or by passing the produce through a downwardly falling curtain or waterfall of the solution. 
Vodena otopina se može primjeniti na proizvod na bilo koji pogodan ili uobičajeni način, npr. potapanjem proizvoda u posudu ili kadu sa otopinom, rasprskavanjem otopine na proizvod, ili propuštanjem proizvoda kroz zavjesu ili tok otopine koji se spušta nadolje.
The boom mountable robotic arm of claim 11 wherein said extension member at least one end of said main beam member includes an oppositely disposed pair of said extension members, and wherein at least one of said at least two includes a pair of insulated support posts, and wherein at least one of said pair of insulated support posts is mounted at said distal end of each said extension member. 
Robotska ruka prema zahtjevu 8, naznačena time, da navedeni nosivi nastavak na barem jednom kraju od navedenog glavnog grednog elementa, obuhvaća jedan nasuprotno položeni par (36, 38) navedenih nosivih nastavaka, te je pritom najmanje jedan od navedena najmanje dva električno izolirana potporna stupa, montiran na spomenutom distalnom kraju od svakog od spomenutih nosivih nastavaka.
Aqueous suspension according to any of claims 1 to 9, characterized in that said water-soluble acid(s) of step b) are dosed in a total amount corresponding to 5 to 40 wt.-% equivalent pure acid based on the dry weight of GNCC provided in step a), more preferably in a total amount corresponding to 10 to 30 wt.-% equivalent pure acid based on the dry weight of GNCC provided in step a), and most preferably in a total amount corresponding to 15 to 25 wt.-% equivalent pure acid based on the dry weight of GNCC provided in step a). 
Postupak prema bilo kojem od zahtjeva 1 do 9, naznačen time da sc navedena kiselina ili navedene kiseline topivo u vodi iz koraka b) doziraju u ukupnoj količini koja odgovara 5 do 40 % tež. ekvivalenta čiste kiseline bazirano na težini suhog GNCC osiguranog u koraku a), poželjnije u ukupnoj količini koja odgovara 10 do 30 % tež. ekvivalenta čiste kiseline bazirano na težini suhog GNCC osiguranog u koraku a), te najpoželjnije u ukupnoj količini koja odgovara 15 do 25 % tež. ekvivalenta čiste kiseline bazirano na težini suhog GNCC osiguranog u koraku a).
The method according to claim 16 wherein the mixture comprises sand and water having a density of more than 1650 kg/m3. 
Postupak sukladno zahtjevu 16 pri čemu mješavina sadrži pijesak 1 vodu gustoće više od 1650 kg/m3.
Example 2. A device according to example 1, wherein the inlet (14) is substantially conical shaped so as to guide said instrument (3) into the passage. 
Uređaj u skladu s patentnim zahtjevom 2, kod kojega ulazni otvor (14) ima uglavnom konusan oblik, tako da se uvodi navedeni instrument (3) u prolaz.
or a pharmaceutically acceptable addition salt thereof, wherein said disease associated with decreased skeletal muscle blood flow is Raynaud's phenomenon or intermittent claudication. The method of claim 2, wherein said compound is selected from the group consisting of: 
(f) bolest povezana sa smanjenim protokom krvi u skeletnim mišićima, poželjno Raynaudov fenomen ili intermitentna klaudikacija, pri čemu se navedeno liječenje sastoji od davanja spoja navedenom pacijentu.
A pharmaceutical composition comprising the compound of claims 1 or 2 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak koja sadrži spoj sukladno patentnim zahtjevima 1 ili 2 1 farmaceutski prihvatljiv nosač.
Hc is selected from the group of 3- or 4-tetrahydropyranyl and 3-tetrahydrofuranyl; 
Hc je odabran iz skupine koju čine: 3- ili 4-tetrahidropiranil i 3-tetrahidrofuranil;
a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:362; 
slijed aminokiselina kodiran polinukleotidnim slijedom koji je najmanje 80% identičan slijedu SEQ ID NO:362;
Paragraph 90. The method of any one of Paragraphs 82-86, wherein P450 enzyme expression in the subject is assessed to determine whether the subject is a poor, intermediate or extensive/ultra rapid P450 metabolizer. 
Spoj za uporabu prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time što se testiranje subjekta radi određivanja da li je subjekt loš, srednji ili ekstenzivni/ultra brzi metabolizator P450, provodi prije ili nakon početka liječenja.
FIGS. 1 to 4 show the data measured during the inoculum preparation process (n=10). 
Slike 1 do 4 pokazuju podatke mjerene tijekom procesa priprave inokuluma (n=10).
Moreover, it was found that in order to smooth 25 welded joints by means of said conventional finishing disc, a processing time of 41 minutes and 36 seconds was required. 
Osim toga je bilo nađeno, da ako se treba izgladiti 25 zavarenih spojeva pomoću navedenog konvencionalnog diska za završnu obradu, bilo je potrebno vrijeme obrade od 41 minute i 36 sekundi.
The composition for use according to any one of the preceding claims, wherein the nucleic acid sequence encoding interleukin-10 encodes IL-10F129S. 
Sastav za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time, da sekvenca nukleinske kiseline koja kodira interleukin-10, kodira IL-10%/**.
For instance at least one quarter of the aliquot may be added over the first half of the period, and at least one quarter of the aliquot over the second half of the period. 
Imunogeni pripravak, naznačen time što sadrži konjugat saharida Hib i najmanje dva dodatna konjugata bakterijskih saharida, gdje konjugat Hib je prisutan u manjoj dozi saharida od srednje doze saharida za sve od najmanje dva dodatna konjugata bakterijskih saharida.
The precipitate was filtered, washed with additional H2O, and dried to give 5-(2-chlorophenyl)pyrimidine-2,4(1H,3H)-dione 6c (0.16 g, 66%) as a white solid. 
Talog se filtrira, ispere s još H20, te osuši kako bi se dobilo 5-(2-klorfeniDpirimidin-2,4(157,3H)-dion 6c (0,16 g, 66 %) u obliku bijele krutine.
The cell pellets were resuspended in 1 mL lysis buffer (50 mM Tris, pH 8.0, 120 mM NaCl, 0.5% NP-40 surfactant, 100 mM NaF; to which protease and phosphatase inhibitors (Roche Diagnostics, Indianapolis, Ind., U.S.A.) had been added before use) and incubated with gentle agitation for 30 minutes at 4° C. The cell lysates were cleared by centrifugation at 13,000 rpm for 10 minutes to remove cell debris. 
Stanične pelete su resuspendirane u 1 mL lizis pufera (Roche Diagnostics, Indianapolis, Indiana, USA) dodano je prije upotrebe i inkubirano uz lagano miješanje 30 minuta kod 40% C. Stanični lizati očišćeni su centrifugiranjem kod 13,000 okr za 10 minuta i odstranjeni stanični nanosi.
On the other hand this type of processing, with cold rolling and subsequent annealing, involves rather important burdens as far as the required costs and time are concerned, whereby it is a steadily more and more felt need in this field that of obtaining a hot rolled strip in dual phase steel which is provided with the same mechanical features of the traditional cold rolled steel. 
Sa druge strane, ovaj tip obrade, sa hladnim valjanjem i zatim žarenjem, uključuje relativno bitne otežavajuće okolnosti što se tiče troškova i utrošenog vremena, pri čemu se stalno sve više i više osjeća potreba u ovom području za dobivanjem toplo valjanih traka u dvofaznom čeliku koji je osiguran sa istim mehaničkim karakteristikama tradicionalnog hladno valjanog čelika.
Description of the invention It has now been found that it is possible to prepare a chewing gum consisting of at least one first region with gum base and a second, fully water-soluble region without gum base, comprising a synergic combination of an effective amount of vegetable extracts selected from magnolia bark extract, green tea extract and combinations thereof and an effective amount of zinc ions, at least partly contained in microgranules which are fully water-soluble. 
Žvakaća guma koja se sastoji od barem prve regije s bazom za gume te barem druge u vodi potpuno topljive regije bez baze za gume, a rečena guma, naznačeno time da ima prisutnost sinergične kombinacije sljedećih: a) učinkovita količina biljnih ekstrakata odabranih od sljedećih: ekstrakt kore magnolije, ekstrakt zelenog čaja i njihova kombinacija, b) učinkovita količina cinkovih iona koji su barem djelomično sadržani u mikrogranulama potpuno topljivim u vodi.
A human engineered antibody or antigen-binding fragment thereof, according to claim 1 or a pharmaceutical composition according to claim 2, for use in the treatment of clinical or pre-clinical Alzheimer's disease. 
Ljudsko modificirano protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevom 1 ili farmaceutski pripravak u skladu s patentnim zahtjevom 2, naznačen time što je namijenjen upotrebi u liječenju kliničke ili pretkliničke Alzheimerove bolesti.
The compound or composition for use according to claim 1, wherein the disease or disorder is liver cancer, wherein the liver cancer is hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, or hemangioma. 
Spoj za uporabu prema zahtjevu 1, naznačen time, da bolest ili poremećaj je limfom grla, ezofagealni limfom, limfom želuca, limfom tankog crijeva, limfom bubrega, maligni limfom kostiju ili hematološki limfom.
The aqueous pharmaceutical suspension according to claim 7, optionally further comprising, by weight/volume (g/100 mL); about 0.01% to about 0.10% of acesulfame potassium or sucralose. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što izborno dodatno sadrži, težinski/volumno (g/100 ml), otprilike 0,01 % do otprilike 0,10 % acesulfam-kalija ili sukraloze.
A pharmaceutical aerosol solution composition according any one of the previous paragraphs wherein the overall formoterol degradation products level is lower than 10% w/w with respect to the theoretical formoterol fumarate content of 6 mcg/actuation and the residual level of formoterol fumarate is higher than 90% w/w with respect to its initial content. 
Farmaceutski pripravak aerosolne otopine prema patentnom zahtjevu 1 u kojem je ukupna razina degradacijskog produkta formoterola niža od 10% w/w prema teorijskom sadržaju formoterol-fumarata od 6 ug/aktiviranju, a preostala razina formoterol-fumarata je viša od 90% w/w prema njegovom početnom sadržaju.
The mixed metal oxidized hydroxide precursor material is represented by the chemical formula: 
Prekursor materijal mješavine oksidiranog hidroksid metala predstavljen je kemijskom formulom:
said DNA probe comprises SEQ ID NO:1 or SEQ ID NO:2 or complement thereof; and/or 
(li) se spomenuta DNA proba sastoji od SEQ ID NO: 1 ili SEQ ID NO: 2 ili njihovih komplementarnih sekvenci; i /ili
The method of claim 1, wherein water content has been added to the MSW in order to achieve a constant mass ratio of water between 0.5 and 2.5 kg water per kg MSW. The method claim 1, wherein cellulase activity is added by inoculation with a selected microorganism that exhibits extra-cellular cellulase activity. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se otpadu dodaje sadržaj vode kako bi se postiglo prikladan sadržaj nevodenih tvari, i/ili što se prikladan sadržaj nevodenih tvari postiže dodavanjem u MSW konstantnog masenog omjera vode između 0,5 1 2,5 kg vode po kg MSW.
VLP according claim 3, wherein the neurological disorder is multiple sclerosis. VLP according to at least one of the above claims, wherein said VLP enters said CNS cell together with the drug encapsulated by the VLP. 
Virusu slična čestica (VLP) za uporabu sukladno barem jednom od gore navedenih patentnih zahtjeva, pri čemu pomenuti VLP ulazi u navedenu stanicu središnjeg živčanog sustava (CNS) zajedno s lijekom koji je enkapsuliran pomoću virusu slične čestice (VLP).
The ELISA was performed according to the general protocol provided with the kit with minor modifications: 
Test ELISA je bio provođen sukladno općeg protokola koji se nalazi u kompletu kemikalija s manjim preinakama:
at least one liquid spraying component (240) located on said frame (200), 
- najmanje jednom komponentom (240) raspršivanja tekućine smještenom na spomenutom okviru (200),
The MDO film according to statement 21, wherein the seal has a seal elongation at failure of about 25% to about 100%, preferably the seal has a seal elongation at failure of about 30% to about 90%, more preferably the seal has a seal elongation at failure of about 35% to about 80%, even more preferably the seal has a seal elongation at failure of about 35% to about 55%, as measured in accordance with ASTM F88/F88M-09. 
Pakirani proizvod u skladu s patentnim zahtjevom 9, ili MDO film u skladu s patentnim zahtjevom 10, naznačen time, da brtva ima elongaciju brtvljenja pri prekidu od oko 25 % do oko 100 %, poželjno brtva ima elongaciju brtvljenja pri prekidu od oko 30 % do oko 90 %, a još je poželjnije da brtva ima elongaciju brtvljenja pri prekidu od oko 35 % do oko 80 %, izmjereno u skladu s ASTM F88/F88M-09.
N-(3-chloro-1H-indole-7-yl)-4-sulfamoylbenzenesulfonamide, N-(3-cyano-4-methyl-1H-indole-7-yl)-3-cyanobenzenesulfonamide, or a pharmacologically acceptable salt thereof or a solvate thereof, and wherein the substance having an EGF inhibitory activity is gefitinib, erlotinib or cetuximab. 
Farmaceutski pripravak obuhvaća spoj sulfonamida u kombinaciji sa supstancom koja ima inhibicijsko djelovanje EGF, naznačen time, što spoj sulfonamida je: N-(3-klor-1H-indol-7-il)-4-sulfamoilbenzensulfonamid,N-(3-cijano-4-metil-1H-indol-7-il)-3-cijanobenzensulfonamid, ili njegova farmakološki prihvatljiva sol ili njegov solvat, i pri čemu supstanca koja ima inhibicijsko djelovanje EGF je gefitinib, erlotinib ili cetuksimab.
characterised in that the first rotor is provided with driving means and has a size such that it can rotate to give an acceleration field of from 25 to 60 km/s2 and the second and third rotors are each provided with a driving means and each have a size and can rotate such as to give an acceleration field of at least 125 km/s2. 
Totiranje rotora; pri čemu se prvi rotor rotira kako bi stvorili polje za ubrzanje od 25 do 60 km/s", i drugi i treći rotor se rotira kako bi stvorili polje ubrzanja od najmanje 125 km/s", osiguravajući mineralnu rastaljenu tvar, pri čemu ta mineralna rastaljena tvar ima rastopinu koji ima slijedeći sastav izražen prema masi oksida:
Matrix metalloproteinase enzymes play a major role in extracellular matrix component degradation and remodelling. 
Enzimi matrične metaloproteinaze imaju veliku ulogu u razgradnji i pregradnji komponenata izvanstaničnog matriksa.
21 Polishing composite If the composite material contracts, this can be 
Ako se kompozitni materijal još steže, ovo se može odgoditi da bi se ostavilo da dođe do hidroskopske ekspanzije prije poliranja
The method according to claim 1, further comprising selecting the binding back (7) to be a V-shaped or U-shaped binding back and selecting the distance (A) to correspond substantially to a depth of the binding back (7). 
Postupak sukladno bilo kojem od prethodnih zahtjeva, naznačen time što je uvez (7) oblika slova V ili U i da udaljenost (A) u osnovi odgovara dubini uveza (7).
The recombinant molecule of claim 5, wherein said nucleic acid sequence encoding said adenoviral E1A protein and said nucleic acid sequence encoding said adenoviral E1B protein are separated by at least 10 kb. 
Rekombinantna molekula ili skup od barem dvije molekule nuklemske kiseline prema zahtjevu 4, naznačena time da su navedena sekvenca nukleinske kiseline koja kodira ELA protein i sekvenca nukleinske kiseline koja kodira barem jedan E1B protein odvojene sa barem 10 kb.
The controlled release composition according to claim 4 for administration once daily. 
Sastav za kontrolirano otpuštanje u skladu s patentnim zahtjevom 1 za primjenu jednom dnevno.
Example 8 Determination of pH of the composition 
Broj objave europskog patenta:
The combination of Claim 1, wherein the modified casing coupling (136) is removable from a casing string, allowing it to be repaired, and then reinstalled in a casing string. 
Kombinacija iz zahtjeva 1, pri čemu je modificirana spojka za zaštitne cijevi (136) odstranjiva od slijedova zaštitnih cijevi, omogućavajući da bude popravljena, 1 zatim Te-instalirana u slijed zaštitnih cijevi.
Transfer apparatus according to any of the claims 1-10, wherein each connection of the coupler (9) to neighbouring carriers (8) comprises a coupler axis about which the coupler (9) is pivotable relative to the carrier (8) comprising said connection. 
Prijenosni uređaj prema bilo kojem zahtjevu 1-10., naznačen time da svaki spoj spojnice (9) sa susjednim nosačima (8) sadrži os spojnice oko koje se okreće spojnica (9) u odnosu na nosač (8) koji sadrži rečeni spoj.
a multitude of administration units A containing dose a of tapentadol that are adapted to be administered during a first administration interval of at least 2 days, a multitude of administration units B containing dose b of tapentadol that are adapted to be administered during a second administration interval of at least 2 days following the first administration interval, optionally, a multitude of administration units C containing dose c of tapentadol that are adapted to be administered during a third administration interval of at least 2 days following the second administration interval, 
(i) mnoštvo jedinica za davanje A koje sadrže dozu a tapentadola, (ii) mnoštvo jedinica za davanje B koje sadrže dozu b tapentadola, i (iii) po izboru, mnoštvo jedinica za davanje C koje sadrže dozu c tapentadola, gdje so navedeno mnoštvo jedinica za davanje A daje tijekom prvog intervala davanja od najmanje 2 dana; navedeno se mnoštvo jedinica za davanje B daje tijekom drugog intervala davanja od najmanje 2 dana nakon prvog intervala davanja; i navedeno se mnoštvo jedinica za davanje C daje tijekom trećeg intervala davanja od najmanje 2 dana nakon drugog intervala davanja.
Accordingly; also the dimensions of the blocks of wood being obtained in the gluing process of the pieces of wood and the like are not critical, that is they can be varied within wide ranges as long as reasonable. 
U skladu s tim, isto tako i dimenzije blokova od drva koji su dobiveni u postupku lijepljenja komada od drva nisu kritične, to jest one se mogu mijenjati u širokim rasponima toliko dugo dok god je to razumno.
The storage system according to claim 1, further comprising at least one additional bin lift device, arranged to receive a storage bin from the first vehicle at the top level of the first grid structure and to convey the storage bin in a vertical direction to the top level of the second grid structure. 
Sustav za skladištenje sukladno patentnom zahtjevu 10 pri čemu je inter-rešetkasto dizalo dalje postavljeno za prijem kontejnera za skladištenje s vozila na najvišoj razini (22) druge strukture rešetke i za okomiti prijenos kontejnera za skladištenje na najvišu razinu (20) prve strukture rešetke.
Thus, the coating can be selected so as to degrade under certain pH conditions within the gastrointestinal tract, thereby selectively release the compound in the stomach or in the ileum or duodenum. 
Tako, prevlaka može biti izabrana tako da se razgradi pri određenim pH vrijednostima unutar probavnog trakta, oslobađajući tako selektivno spoj u želucu ili crijevu ili dvanaestercu.
The isolated cell according to claim 12, wherein the cell is a mouse embryonic stem cell. 
Izolirana stanica u skladu s patentnim zahtjevom 12, naznačena time, da je stanica mišja embrionalna matična stanica.
A solid system for the modified release in accordance with any of claims 1-3, wherein said active ingredients are in the form of microgranules or microcapsules dispersed in the polymer matrix. 
Čvrsti sustav za modificirano oslobađanje u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što su navedeni aktivni sastojci u obliku mikrogranula ili mikrokapsula disperziranih u polimernom matriksu.
This fraction contains residues of cell culture impurities and aggregates forms of IL-18BP. 
Ova frakcija sadrži nečistoće iz stanične kulture te agregatne oblike IL-18BP.
The granules were screened through a 200 um sieve. 
Granule se prosiju kroz 200 um sito i sakupe.
In the prior art, several building methods are known in which lightweight wall elements are used. 
U stanju tehnike poznati su neki postupci gradnje u kojima se koriste lagani zidni elementi.
The solution was stirred to dissolve the solids then the flask was placed in an ice/water bath and the solution was stirred for 30 minutes. 
Otopina je bila miješana da bi se otopile krutine i tada je tikvica bila stavljena u kupelj led/voda 1 otopina je bila miješana 30 minuta.
Number of animals 
Broj međunarodne objave:
The method of claim 17, wherein the human retinal pigmented epithelial cells are ARPE-19 cells deposited with the American Type Culture Collection (ATCC) as Accession No. 
Postupak prema patentnom zahtjevu 11, naznačen time što su humane retinalne pigmentirane epitelne stanice ARPE-19 stanice deponirane kod American Type Culture Collection (ATCC) kao pristupni br.
The method of claim 4, wherein the randomizing codons are selected from the group NNS and NNK, such as wherein the randomizing codons are incorporated at positions encoding at least one loop region selected from the group consisting of residues at or about positions 13-16, 22-28, 38-43, 51-54, 60-64, and 75-81 of SEQ ID NO: 144-146. 
Metoda iz patentnog zahtjeva 5, pri čemu su nasumični kodoni izabrani iz grupe NNS i NNK, tako da su nasumični kodoni uvršteni na pozicijama kodiranja najmanje jedne regije petlje izabranih iz grupe koja se sastoji od ostataka u/ ili oko pozicija 13-16, 22-28, 38-43, 51-54, 60-64, i 75-81 od SEQ ID BR: 142, 143 i 147-151.
The lever.arrangement can be composed of two co-parallel pairs of levers. 
Mehanizam s polugom može biti sastavljen od dva paralelna para poluga.
The method of claims 1-9, wherein the vaccine comprises IPV types 1, 2 and 3 adsorbed onto aluminium hydroxide or aluminium phosphate or a mixture of both, wherein adsorption takes place either before mixing with antigen other than IPV, or wherein adsorption takes place after mixing with antigen other than IPV. 
Postupak u skladu s patentnim zahtjevima 1-9, naznačen time što cjepivo sadrži IPV tipove 1, 2 1 3, adsorbirane na aluminijev hidroksid ili aluminijev fosfat ili smjesu istih, gdje se adsorciju provodi bilo prije miješanja s antigenom koji nije IPV, ili gdje se adsorciju provodi nakon miješanja s antigenom koji nije IPV.